| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/JBMR.3081 |
| P698 | PubMed publication ID | 28071822 |
| P2093 | author name string | Nelson B Watts | |
| Edward F McCarthy | |||
| Paul D Miller | |||
| Rachel Patterson | |||
| Stephanie Martinez | |||
| Deborah Aggers | |||
| Erin Carrithers | |||
| Tina Savage | |||
| P2860 | cites work | Effect of Teriparatide on Healing of Atypical Femoral Fractures: A Systemic Review | Q26771709 |
| PINP as a biological response marker during teriparatide treatment for osteoporosis | Q26859267 | ||
| Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate | Q33587793 | ||
| Bisphosphonates: from the laboratory to the clinic and back again | Q33697467 | ||
| Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis | Q34003925 | ||
| Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females | Q34170152 | ||
| Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate | Q34765502 | ||
| Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study | Q35556799 | ||
| Effectiveness of Teriparatide on Fracture Healing: A Systematic Review and Meta-Analysis | Q36229660 | ||
| Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution | Q36758889 | ||
| Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy | Q37023006 | ||
| Osteoporosis treatments and adverse events | Q37468369 | ||
| Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates | Q37738185 | ||
| Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects | Q37956180 | ||
| Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research | Q38109833 | ||
| Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research | Q44039263 | ||
| Incidence of atypical nontraumatic diaphyseal fractures of the femur | Q44364497 | ||
| Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography | Q44578541 | ||
| Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis | Q46065467 | ||
| Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography | Q46282127 | ||
| Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters | Q46283621 | ||
| Severely suppressed bone turnover and atypical skeletal fragility | Q46560284 | ||
| Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial | Q47618876 | ||
| Comparison between different bone treatments on areal bone mineral density (aBMD) and bone microarchitectural texture as assessed by the trabecular bone score (TBS). | Q50453830 | ||
| Three years of alendronate treatment does not continue to decrease microstructural stresses and strains associated with trabecular microdamage initiation beyond those at 1 year. | Q50504521 | ||
| Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features | Q57779060 | ||
| Epidemiology of diaphyseal femoral fracture | Q58166157 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 1027-1033 | |
| P577 | publication date | 2017-01-10 | |
| P1433 | published in | Journal of Bone and Mineral Research | Q15750941 |
| P1476 | title | Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates. | |
| P478 | volume | 32 |
| Q88417439 | A proposal for an atypical femur fracture treatment and prevention clinical practice guideline |
| Q52600423 | Anabolic agents: what is beyond osteoporosis? |
| Q89304708 | Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures |
| Q60947531 | Hip Fracture Nonunions: Diagnosis, Treatment, and Special Considerations in Elderly Patients |
| Q92194249 | Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society |
| Q39255870 | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. |
| Q88723384 | Subtrochanteric and diaphyseal femoral fractures in hypophosphatasia-not atypical at all |
| Q47686693 | Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur. |
| Q89896441 | The Treatment of Acute Diaphyseal Long-bones Fractures with Orthobiologics and Pharmacological Interventions for Bone Healing Enhancement: A Systematic Review of Clinical Evidence |
| Q89560528 | The biology and treatment of acute long-bones diaphyseal fractures: Overview of the current options for bone healing enhancement |
Search more.